Acadia Stock Crashes After FDA Rejects Key Drug — Analyst Sees Huge Delay

The Food and Drug Administration rejected Acadia Pharma’s Nuplazid for patients with dementia-related psychosis on Monday, leading ACAD stock to plunge to its lowest point in two years.
Read More